Home Breast Cancer BRIEF-Roche: Update On Genentech’s Breast Cancer Therapy

BRIEF-Roche: Update On Genentech’s Breast Cancer Therapy

96
0

Sept 13 (Reuters) – Roche Holding AG:

* GENENTECH’S FIXED DOSE SUBCUTANEOUS COMBINATION OF PERJETA AND HERCEPTIN SHOWED NON-INFERIORITY WHEN COMPARED TO INTRAVENOUS FORMULATIONS FOR PEOPLE WITH HER2-POSITIVE BREAST CANCER

* DATA WILL BE SUBMITTED TO HEALTH AUTHORITIES AROUND WORLD, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY Source text: [bit.ly/2lKvy1B] Further company coverage: (Berlin Speed Desk)

This site uses Akismet to reduce spam. Learn how your comment data is processed.